SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:prod.swepub.kib.ki.se:144373837"
 

Sökning: onr:"swepub:oai:prod.swepub.kib.ki.se:144373837" > FIRST LINE TREATMEN...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005582naa a2200517 4500
001oai:prod.swepub.kib.ki.se:144373837
003SwePub
008240902s2020 | |||||||||||000 ||eng|
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1443738372 URI
0247 a https://doi.org/10.1136/annrheumdis-2020-eular.31312 DOI
040 a (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a vet2 swepub-contenttype
072 7a kon2 swepub-publicationtype
1001 a Sena, AG4 aut
2451 0a FIRST LINE TREATMENT WITH CONVENTIONAL SYNTHETIC DISEASE MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS: A MULTINATIONAL POPULATION-BASED COHORT FROM 14 REAL WORLD HEALTHCARE DATABASES AND 9 COUNTRIES - REALITY VERSUS GUIDELINES
264 c 2020-06-02
264 1b BMJ,c 2020
520 a Treatment guidelines recommend early initiation of csDMARDs following diagnosis of rheumatoid arthritis (RA), with methotrexate (MTX) as first-line therapy. Scarce evidence exists on adherence to this guidanceObjectives:To characterize first-line csDMARD treatment during the first year following an RA diagnosis.Methods:14 real world databases (3 Primary care, 6 primary/secondary care records, 5 claims) from 9 countries were included, all mapped to the OMOP common data model.Patients were included on the earliest event of: 1st diagnosis of RA or 1st DMARD prescription with an RA diagnosis within 30 days. Patients were >18 years-old, required 1+ year pre-index data, and at least 1-year follow-up. Study period covered 2000-2018. Previous users of DMARDs or non-RA inflammatory arthritis history were excluded. Only MTX, Hydroxychloroquine (HCQ), Sulfasalazine (SSZ) and Leflunomide (LEF) were available in all databases.Results:We identified 323,547 eligible participants. Large variation was observed internationally (Figure 1). MTX as first-line monotherapy ranged from 33.3% to 74.5%, and in combination with HCQ from 2.1% to 6.7%. Three additional csDMARDs were used as first-line: HCQ in 10.1% to 30.2%, SSZ in 0.9% to 28.7%, and LEF in 1.8% to 15.2%.Figure 1.First line csDMARD treatment during 1yr from first observed RA diagnosisConclusion:We report wide heterogeneity of first-line csDMARDs regimens internationally. Despite recommendations for MTX to be first line therapy, data suggest that a large proportion of patients receive alternative csDMARD.Disclosure of Interests: :Anthony G Sena Shareholder of: J&J shares, Grant/research support from: Full-time employment salary from Janssen, Consultant of: Full-time employment salary from Janssen, Employee of: Janssen employee, Paid instructor for: Janssen employee, Speakers bureau: Janssen employee, Denis Granados: None declared, Nigel Hughes Shareholder of: J&J shares, Grant/research support from: Full-time employment salary from Janssen, Consultant of: Janssen employee, Employee of: Janssen employee, Paid instructor for: Janssen employee, Speakers bureau: Janssen employee, WALID FAKHOURI Shareholder of: E Lilly Shares, Employee of: Eli Lilly and Company, Antje Hottgenroth Shareholder of: Eli Lilly shares, Employee of: Lilly Deutschland GmbH, Raivo Kolde: None declared, Sulev Reisberg: None declared, Carmen Olga Torre: None declared, Talita Duarte-Salles: None declared, Yesika Díaz: None declared, Jose Felipe Golib-Dzib Grant/research support from: Full-time employment salary from Janssen, Employee of: Yes, Janssen employee, Paid instructor for: Janssen Employee, Speakers bureau: Janssen Employee, Emily S. Brouwer Shareholder of: J&J shares, Takeda shares, Grant/research support from: Full-time employment salary from Janssen, Consultant of: Janssen employee, Employee of: Janssen employee, Paid instructor for: Janssen Employee, Speakers bureau: Janssen Employee, Edward Burn: None declared, Jennifer Lane: None declared, David Vizcaya Employee of: Bayer, Sara Bruce Wirta Employee of: Janssen-Cilag Sweden AB, Marcel de Wilde: None declared, Katia Verhamme: None declared, Peter Rijnbeek: None declared, Elke Theander Employee of: Janssen-Cilag Sweden AB, Katerina Chatzidionysiou Consultant of: AbbVie, Pfizer, Lilly., Daniel Prieto-Alhambra Grant/research support from: Professor Prieto-Alhambra has received research Grants from AMGEN, UCB Biopharma and Les Laboratoires Servier, Consultant of: DPA’s department has received fees for consultancy services from UCB Biopharma, Speakers bureau: DPA’s department has received fees for speaker and advisory board membership services from Amgen, Patrick Ryan: None declared
7001 a Granados, D4 aut
7001 a Hughes, N4 aut
7001 a Fakhouri, W4 aut
7001 a Hottgenroth, A4 aut
7001 a Kolde, R4 aut
7001 a Reisberg, S4 aut
7001 a Torre, CO4 aut
7001 a Duarte-Salles, T4 aut
7001 a Diaz, Y4 aut
7001 a Golib-Dzib, JF4 aut
7001 a Brouwer, ES4 aut
7001 a Burn, E4 aut
7001 a Lane, J4 aut
7001 a Vizcaya, D4 aut
7001 a Wirta, SB4 aut
7001 a De Wilde, M4 aut
7001 a Verhamme, K4 aut
7001 a Rijnbeek, P4 aut
7001 a Theander, E4 aut
7001 a Chatzidionysiou, Ku Karolinska Institutet4 aut
7001 a Prieto-Alhambra, D4 aut
7001 a Ryan, P4 aut
7102 a Karolinska Institutet4 org
7730 t ANNALS OF THE RHEUMATIC DISEASESd : BMJg 79, s. 327-327q 79<327-327x 0003-4967x 1468-2060
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:144373837
8564 8u https://doi.org/10.1136/annrheumdis-2020-eular.3131

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy